É. Dansin

发表

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

E. Felip, F. de Marinis, G. Altavilla, 2012, The Lancet. Oncology.

[Stereotactic radiotherapy for lung cancer: Non-invasive real-time tumor tracking].

J. Bibault, T. Lacornerie, E. Lartigau, 2010, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors.

O. Corneloup, G. Ferretti, D. Planchard, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes

N. Girard, D. Planchard, P. Dubray-Longeras, 2021, Targeted Oncology.

Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.

M. Copin, J. Soria, B. Besse, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors

J. Schellens, J. Beijnen, J. Bonneterre, 2006, Clinical Cancer Research.

Association between lung cancer somatic mutations and occupational exposure in never-smokers

P. Dumont, D. Moro-Sibilot, C. Paris, 2017, European Respiratory Journal.

Report of Eight Recent Cases of Locally Advanced Primary Pulmonary Artery Sarcomas: Failure of Doxorubicin-Based Chemotherapy

N. Penel, É. Dansin, S. Taieb, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

G. Zalcman, P. Fournel, C. Chouaid, 2014, BMC Cancer.

Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.

N. Girard, J. Mazières, C. Lindsay, 2016, Lung cancer.

Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.

G. Giaccone, D. Lacombe, E. Smit, 2004, European Journal of Cancer.

Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

J. Soria, J. Mazières, J. Trédaniel, 2015, Clinical Cancer Research.

MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.

P. Garrido, F. Griesinger, É. Dansin, 2012, Lung cancer.

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

N. Pavlakis, Yi-long Wu, L. Crinò, 2010, The Lancet. Oncology.

Contribution of Next-generation Sequencing in a Case of Metastatic Breast Carcinoma with Pulmonary Lesions

J. Bonneterre, É. Dansin, O. Abramovici, 2016 .

Phase II combination of gefitinib and docetaxel for advanced or metastatic non-small cell lung cancer: clinical results and biological monitoring

E. Lemarié, D. Khayat, S. Oudard, 2006, Targeted Oncology.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

R. Govindan, A. Dingemans, A. Shaw, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

B. Milleron, O. Molinier, G. Zalcman, 2016, European Respiratory Journal.

[Pleuro-pulmonary metastases from a malignant mesothelioma of the tunica vaginalis].

M. Copin, I. Hysi, É. Dansin, 2011, Revue des maladies respiratoires.

Subclinical alveolitis in immunological systemic disorders. Transition between health and disease?

C. Marquette, B. Wallaert, M. Dugas, 1990, The European respiratory journal.

Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort

N. Girard, T. Molina, L. Thiberville, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sequential versus concurrent chemo-radiation (RT-CT) in locally advanced non small cell lung cancer (NSCLC): A French randomized phase III trial of GLOT-GFPC (NPC 95-01 study)

J. Daurès, P. Souquet, P. Fournel, 2001 .

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study

D. Planchard, F. Guisier, M. Wislez, 2022, Cancers.

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial

N. Penel, A. Adenis, É. Dansin, 2018, BMC Cancer.

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

D. Gandara, Melissa L. Johnson, S. Novello, 2022, Nature Medicine.

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

M. Socinski, R. Govindan, A. Shaw, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL)

N. Pavlakis, L. Crinò, N. Thatcher, 2008 .

LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683

O. Riesterer, C. Faivre-Finn, G. Zalcman, 2020 .

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

B. Milleron, O. Molinier, S. Laporte, 2011, The Lancet.

Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).

R. Ramlau, M. Krzakowski, J. Jassem, 2014, Clinical lung cancer.

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

F. Cappuzzo, S. Peters, J. Mazières, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

S. Peters, E. Felip, J. Mazières, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Olivier Lantz, Laurence Zitvogel, Clotilde Théry, 2015, Oncoimmunology.

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].

A. Furlan, M. Wislez, D. Tulasne, 2018, Revue des maladies respiratoires.

High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form.

M. Copin, M. Lesaffre, D. Tulasne, 2016, Lung cancer.

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

H. Blanché, J. Trédaniel, G. Zalcman, 2015, European Respiratory Journal.

OA 03.01 Prevalence of Autoimmune Diseases in Thymic Epithelial Tumors (TET) Insights from RYTHMIC

N. Girard, L. Thiberville, J. Mazières, 2017 .

Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network.

N. Girard, T. Molina, L. Thiberville, 2021, European journal of cancer.

1899P Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET)

N. Girard, T. Molina, L. Thiberville, 2020 .

Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort

N. Girard, L. Thiberville, B. Dubray, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The future: surgical advances in MEN1 therapeutic approaches and management strategies.

S. Sadowski, É. Dansin, F. Triponez, 2017, Endocrine-related cancer.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

N. Girard, J. Mazières, D. Moro-Sibilot, 2017, Oncotarget.

Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials

J. Bonneterre, N. Penel, A. Adenis, 2010, Investigational New Drugs.

Prognostic factors among cancer patients with good performance status screened for phase I trials

J. Bonneterre, R. Beuscart, N. Penel, 2008, Investigational New Drugs.

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.

C. Chouaid, R. Gervais, P. Saulnier, 2020, The Lancet. Oncology.

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

D. Planchard, F. Guisier, M. Wislez, 2019, Lung cancer.

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3

J. Pignon, C. Chouaid, E. Quoix, 2011, European Respiratory Journal.

Comparative cost-effectiveness of three strategies for guiding second-line erlotinib initiation in non small-cell lung cancer: a French prospective multicenter study (ERMETIC Project Part 3) Short title: Erlotinib cost-effectiveness analysis in second-line lung cancer therapy

Isabelle, C. Chouaid, É. Dansin, 2011 .

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

D. Moro-Sibilot, B. Besse, R. Descourt, 2017, Oncotarget.

[Efficacy and tolerance of bevacizumab in non-small cell lung cancer: preliminary report].

J. Mazières, É. Dansin, 2008, Revue de pneumologie clinique.

Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study.

J. Mazières, C. Dubos-Arvis, É. Dansin, 2020, Respiratory medicine and research.

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.

O. Riesterer, C. Faivre-Finn, A. Dunant, 2021, The Lancet. Oncology.

Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study.

J. Daurès, P. Souquet, P. Fournel, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by 18F-Misonidazole PET/CT in Patients with Non–Small Cell Lung Carcinoma (RTEP5 Study)

Maximilien Vermandel, Pierre Vera, Bernard Dubray, 2017, The Journal of Nuclear Medicine.

Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.

M. Copin, F. Escande, M. Wislez, 2019, Clinical lung cancer.

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.

R. Govindan, S. Ou, A. Shaw, 2019, Lung cancer.

9170 Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390)

N. Pavlakis, L. Crinò, N. Thatcher, 2009 .

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.

J. Daurès, B. Massuti, R. Descourt, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Necrosis- and apoptosis-related Met cleavages have divergent functional consequences

M. Copin, H. Drobecq, N. Delhem, 2015, Cell Death and Disease.

Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care

C. Fournier, N. Penel, L. Mortier, 2010, British Journal of Cancer.

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer

B. Milleron, O. Molinier, J. Trédaniel, 2013, European Respiratory Journal.

Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study

O. Le Rouzic, A. Scherpereel, O. Cottencin, 2018, BMC Cancer.

1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C

T. Mok, D. Gandara, S. Novello, 2021, Annals of Oncology.

Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized Evidence.

R. Rami-Porta, P. V. Van Schil, E. Fadel, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report

F. Révillion, A. Carnot, Y. Robin, 2015, Case Reports in Oncology.

Asymptomatic Pelvic Metastasis from Thymic Carcinoma: A Case Report

É. Dansin, F. Narducci, H. Porte, 2014, Case Reports in Oncology.

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.

O. Molinier, D. Moro-Sibilot, F. Barlesi, 2020, Clinical lung cancer.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients

L. Thiberville, J. Mazières, D. Moro-Sibilot, 2018, ERJ Open Research.

[Neuroendocrine tumors of the breast: Myth or reality? A systematic review].

J. Bonneterre, Y. Robin, É. Dansin, 2018, Bulletin du cancer.

Treatment strategies for thymic carcinoma in a real-life setting: Insights from the rythmic network.

N. Girard, T. Molina, L. Thiberville, 2020 .

MA07.05 Immune Checkpoint Inhibitor (ICPi) Re-Challenge: Outcomes Analysis in a French National Cohort of Non-Small-Cell Lung Cancer (NSCLC) Patients

N. Girard, O. Molinier, F. Barlesi, 2019, Journal of Thoracic Oncology.

A Multicenter Study to Assess a Systematic Screening of Occupational Exposures in Lung Cancer Patients

F. Dutheil, B. Clin, M. Boulanger, 2023, International journal of environmental research and public health.

1096O Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study

E. Baudin, D. Hörsch, C. Grohé, 2021, Annals of Oncology.

Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer

J. Vansteenkiste, P. Zatloukal, N. Dohollou, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes of thymic epithelial tumors (TETs) with pleural metastases: Real-world insight from RYTHMIC.

N. Girard, L. Thiberville, B. Besse, 2021 .

G. Zalcman, P. Fournel, C. Chouaid, 2014, BMC Cancer.

Central nervous system metastases in thymic epithelial tumors: a brief report of real-world insight from RYTHMIC.

T. Molina, L. Thiberville, B. Besse, 2021, Journal of Thoracic Oncology.

9168 Safety and efficacy of first-line bevacizumab-based therapy in advanced non-small cell lung cancer (NSCLC): results of the SAiL study (MO19390)

N. Pavlakis, Yi-long Wu, L. Crinò, 2009 .

Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN).

J. Soria, J. Mazières, D. Moro-Sibilot, 2013 .

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

[Primary soft tissue sarcoma of the chest in adults: a retrospective study of 40 cases].